FIG 4.

Blocking entry through CXCR6 limits SIVagmSab replication in primary sabaeus lymphocytes. (A) 293T cells were transfected with plasmids encoding sabaeus CCR5, CXCR6, GPR15, GPR1, or APJ or an empty vector (10 ng) in conjunction with sabaeus CD4-31 (1 μg). Cells were treated for 1 h with the CXCR6 ligand CXCL16 (500 ng/ml), the CCR5 blocker maraviroc (MVC) (15 μM), or the vehicle alone and then infected with a luciferase reporter pseudotype containing SIVagmSab92018ivTF Env. Cells were lysed and luciferase content was measured 72 h later. Infections were carried out in triplicate, and data (means ± standard deviations) are representative of results from 3 replicate experiments. (B) Sabaeus PBMC were stimulated for 3 days with PHA/IL-2; treated for 1 h with CXCL16 (500 ng/ml), maraviroc (15 μM), both blocking agents, or the vehicle alone; and then infected in duplicate with SIVagmSab92018ivTF using 5 ng of viral p27 Gag antigen. Infection was measured as p27 production in the supernatant at day 7 and is shown for each treatment as a percentage of the value for the vehicle alone (no drug). Each symbol represents data from a different animal's PBMC, and shown are means and standard deviations under each condition. *, P < 0.05; **, P < 0.01 (two-tailed paired t test). dpi, days postinfection.